Alvotech Closes $165M Public Offering and Private Placement, Underwriters Fully Exercise Option
ALVO sits 32% above its 52-week low of $2.94.
Summary
Alvotech finalized a $165 million capital raise through a public offering and private placement, including the full exercise of the underwriters' option, leading to approximately 12.7% dilution.
Key Events · Financing and Capital Events · ALVO
-
Capital Raise Finalized
Alvotech closed its public offering and concurrent private placement, raising approximately $165 million in gross proceeds.
-
Underwriters' Option Fully Exercised
The underwriters fully exercised their option to purchase an additional 3,400,000 ordinary shares, contributing to the total capital raised.
-
Significant Dilution
The offering and private placement involved the issuance of 43,893,333 new ordinary shares, resulting in approximately 12.7% dilution for existing shareholders.
-
Proceeds for Biosimilar Development
Net proceeds will fund the continued development of biosimilar assets, working capital, general corporate purposes, and potentially debt repayment.
Analysis · ALVO · Life Sciences
Alvotech has successfully closed its public offering and concurrent private placement, raising a total of $165 million. This capital raise, which includes the full exercise of the underwriters' option, results in approximately 12.7% dilution for existing shareholders. While dilutive, the proceeds are crucial for funding the continued development of its biosimilar assets, working capital, and general corporate purposes, extending the company's operational runway.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.94 to $9.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.